This week's Biotech Scorecard: Catching up on non-Prasad work.
-- $ALDX is complaining about short sellers in the run-up to an FDA approval decision. Red flag!
-- The $VRTX era of frictionless commerce is coming to an end. IgAN competition.
-- $SRPT at a CEO crossroads.
https://t.co/QIgn9e15Hd
